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a  b  s  t  r  a  c  t
Objectives:  In 2009–2010  a Portuguese  consortium  was  created  to implement  the  methodologies  pro-
posed  by the  Dose  Datamed  II  (DDM2)  project,  aiming  to collect  data  from  diagnostic  X-ray  and  nuclear
medicine  (NM)  procedures,  in  order  to  determine  the  most  frequently  prescribed  exams  and  the associ-
ated  ionizing  radiation  doses  for the  Portuguese  population.  The  current  study  is  the  continuation  of this
work,  although  it focuses  only  on  NM  exams  for the  years  2011  and  2012.
Material  and  methods:  The  annual  frequency  of  each of  the  28 selected  NM  exams  and  the  average admin-
istered  activity  per  procedure  was  obtained  by means  of  a  nationwide  survey  sent  to the  35 NM  centres
in  Portugal.
Results:  The  results  show  a reduction  of the  number  of cardiac  exams  performed  in the last  two  years
compared  with  2010,  leading  to  a reduction  of the  annual  average  effective  dose  of Portuguese  pop-
ulation  due  to NM exams  from  0.08 mSv  ± 0.017  mSv/caput  to 0.059  ±  0.011  mSv/caput  in  2011  and
0.054  ± 0.011  mSv/caput  in 2012.  Portuguese  total  annual  average collective  effective  dose  due  to  med-
ical  procedures  was estimated  to be  625.6 ±  110.9  manSv  in 2011  and  565.1 ±  117.3 manSv  in 2012,  a
reduction  in  comparison  with  2010  (840.3 ±  183.8  manSv).
Conclusions:  The  most  frequent  exams  and the  ones  that contributed  the  most for total  population  dose
were  the  cardiac  and  bone  exams,  although  a decrease  observed  in  2011  and  in  2012  was  veriﬁed.  The
authors  intend to  perform  this  study  periodically  to  identify  trends  in  the  annual  Portuguese  average
effective  dose and  to help  to raise  awareness  about  the  potential  dose  optimization.
©  2014  Elsevier  España,  S.L.U.  and  SEMNIM.  All  rights  reserved.
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Estimación  de  la  dosis  colectiva  en  la  población  portuguesa  de  los  an˜os  2011  y
2012,  debido  a  los  exámenes  de  medicina  nuclear
r  e  s  u  m  e  n
Objetivo:  En 2009  y 2010 un consorcio  portugués  ha  sido  creado  para  implementar  las metodologías
propuestas  por  el  proyecto  europeo  Datamed  II (DDM2),  con  el  objetivo  de  coleccionar  datos de  proced-
imientos  de  radiología  de  diagnóstico  y  medicina  nuclear  (MN)  más frecuentes,  así  como  la  dosis  asociada
en  la  población  portuguesa.  Este  estudio  es una  continuación  del trabajo,  que  se  centrará  en  los  datos  de
MN  para  los an˜os  de  2011  y 2012.
Material  y  Métodos:  La  frecuencia  anual  de  cada  uno  de  los 28 exámenes  de MN seleccionados  y la
actividad  media  administrada  por procedimiento  se  obtuvieron  a través  de  una  encuesta  enviada  a los  35
departamentos  de MN  en Portugal.
Resultados:  Los resultados  muestran  una  reducción  drástica  en  el  número  de  procedimientos  cardiacos
en  los últimos  dos  an˜os,  lo  que  tiene  como  consecuencia  una  reducción  de  la  dosis  efectiva anual  en
la población  portuguesa  derivado  de  procedimientos  de  MN  de  0,08mSv±0,017  mSv/caput  en  2010,  a
0,059±0,011  mSv/caput  in 2011  y 0,054±0,011  mSv/caput  in  2012.  La dosis  efectiva  colectiva  media  en
la  población  portuguesa  es  estimada  en  625.6  ± 110.9  manSv  en 2011,  y  565.1  ± 117.3  manSv  en  2012.
Conclusiones:  Los exámenes  cardiacos  y óseos  fueron  más  frecuentes  y  los que  más  contribuyeron  para
la  dosis  total  de  la  población,  aunque  se  veriﬁcó  una  disminución  en  2011  y en 2012.  Los autores  de
este  trabajo  pretenden  realizar  este  tipo  de estudios  periódicamente  para  identiﬁcar  tendencias  en  los
diferentes  procedimientos  de MN y ayudar  a aumentar  la  conciencia  de los  profesionales  de  MN sobre
este  asunto.
©  2014 Elsevier  España,  S.L.U.  y SEMNIM.  Todos  los  derechos  reservados.
Introduction
The use of ionizing radiation for medical purposes has increased
over the past decades, contributing to over 95% of man-made
radiation exposure.1 Even if image quality improved, allowing for
more accurate diagnoses, a signiﬁcant increase of the dose deliv-
ered to each patient also occurred. Procedures such as computed
tomography (CT), interventional procedures, and cardiac nuclear
medicine are thought to be the main contributors to such an
increase in exposure. International organizations such as the United
Nations Scientiﬁc Committee on the Effects of Atomic Radiation
(UNSCEAR) and the European Commission (EC) published several
reports in which increased values of worldwide collective dose
are presented.2,3 The EC has concerns about the wide differences
between the reported results of population dose estimations from
different European countries with similar healthcare levels, which
may be due to the absence of a common European methodology.
This led to the creation of a multinational European project, in 2004,
the Dose Datamed I (DDM1), in which a group of countries with tra-
dition in conducting studies of population exposure participated,
with the aim of ﬁnding a common methodology. Based on the expe-
rience of 10 European countries, Radiation Protection no. 154 was
created.4 This document provides practical guidance to create a
harmonized system for assessing patient doses in Member States in
order to compare national population doses in the future. Guidance
is provided to assess dose due to medical X-ray imaging and nuclear
medicine (NM) procedures. It should be noted that there has been
a long history of carrying out periodic reviews of the population
exposure in most countries participating in DDM I, in contrast with
what happens in Portugal.
In 2009–2010 the European Commission ﬁnanced the project
Dose Datamed II (DDM2),5 a follow-up study of DDM1, also
called “Study on European Population Doses From Medical Expo-
sure”, aiming to collect data from diagnostic X-ray and nuclear
medicine procedures in order to determine the most frequently
prescribed exams and the associated collective doses in the Euro-
pean population.6 Portugal, together with other 35 countries
participated in this study.7 For such, a Portuguese consortium was
created, to potentiate the implementation of the methodologies
proposed by DDM2.8 This led to an estimation of the dose to the
Portuguese Population of ∼1 mSv  caput−1 for the year 2010 and, of
particular interest to this work, of 0.080 ± 0.0017 mSv/caput due to
nuclear medicine examinations.9
The current study aims to be both a continuation and an
improvement of the previous work, focusing only on the popu-
lation doses to nuclear medicine procedures, for the years 2011
and 2012, and comparing them with the results obtained in 2010.
Radiation doses due to radiodiagnostic exams will be analyzed else-
where. The most frequent nuclear medicine exams and those that
contribute the most for the annual collective dose were assessed.
The Portuguese results are also compared with those available for
other European Countries. Finally, the yearly trends of population
dose and annual frequencies of different nuclear medicine exams
were also analyzed.
Material and methods
The methodology used in this study was  based on the report
Radiation Protection 154 (RP154). For nuclear medicine practices,
the RP154 recommends the implementation of a nationwide sur-
vey to the extant nuclear medicine centres.4 A table with the most
common nuclear medicine procedures is proposed in the report,
involving the most utilized radionuclides divided in six major
types of diagnostic exams (bone, heart, thyroid, lung, kidney and
the remainders). This consists of 28 NM examinations (procedure,
radionuclide and chemical form) as presented in Table 1.
A nationwide survey was sent to all 35 nuclear medicine cen-
tres in Portugal. The centres were invited to ﬁll in a ﬁle with the
annual frequency of each exam, as well as the average administered
activity per procedure. In addition, each NM centre could include
a list of exams they considered relevant (high number of patients
performing the exam or high administered activity). For the NM
centres which had this information available, only data from adults
(>18 yrs) were included. In Portugal, a total of 34 NM departments
were identiﬁed in 2011 and 35 in 2012, unlike the 32 centres in
2010. The use of different radionuclides highly affects the effec-
tive dose per examination, so it is important to guarantee the same
radionuclide is being used for the same procedure.
Of the 34 identiﬁed centres in 2011, four did not possess any
statistical data and the other six did not reply. In 2012 from the
universe of 35 centres, four did not possess any statistical data and
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Table  1
Conversion coefﬁcients used for the 28 nuclear medicine radiopharmaceuticals considered in this study. The values are with agreement with DDM2-Portugal and ICRP 53,10
8011 and 106.12
Nuclear medicine procedure Radionuclide and chemical form Conversion coefﬁcient (mSv/MBq)
1. Bone imaging 99mTc – phosphates and phosphonates 5.70 × 10−3
2. Myocardial perfusion with thallium 201Tl – chloride 2.20 × 10−1
3. Myocardial perfusion with Tetrofosmin (rest) 99mTc – tetrofosmin 7.60 × 10−3
4. Myocardial perfusion with Tetrofosmin (exercise) 99mTc – tetrofosmin 7.00 × 10−3
5. Myocardial perfusion with MIBI (rest) 99mTc – MIBI 9.00 × 10−3
6. Myocardial perfusion with MIBI (exercise) 99mTc – MIBI 7.90 × 10−3
7. Myocardial perfusion (PET) 18F – FDG 1.90 × 10−2
8. Myocardial perfusion (PET) 15O – H2O 9.30 × 10−4
9. Positron emission tomography 18F – FDG 1.90 × 10−2
10. Positron emission tomography + diagnostic CT 18F – FDG 1.90 × 10−2
11. Thyroid metastases (after ablation, uptake 0%) 131I – iodide 6.10 × 10−2
12. Thyroid imaging (oral uptake, no blocking) 99mTc – pertechnetate 1.40 × 10−2
13. Thyroid imaging (35% thyroid uptake) 123I – iodide 2.20 × 10−2
14. MUGA, cardiac blood pool, cardiac blood ﬂow (equilibrium) 99mTc – DTPA 4.90 × 10−3
15. MUGA, cardiac blood pool, cardiac blood ﬂow (equilibrium) 99mTc – Tc-labelled erythrocytes 7.00 × 10−3
16. Dopamine transporter imaging (parkinsonism) 123I– CIT 5.00 × 10−2
17. Dopamine transporter imaging (parkinsonism) 123I – ioﬂupane (DatScan) 2.40 × 10−2
18. Lung perfusion 99mTc – MAA  1.10 × 10−2
19. Neuroendocrine tumours/somatostatin receptors imaging 111In – pentetreotide (OctreoScan) 1.20 × 10−1
20. Renal imaging 99mTc – DMSA 8.80 × 10−3
21. Renal imaging 99mTc – MAG3 7.00 × 10−3
22. Renal imaging 99mTc – DTPA 4.90 × 10−3
23. Parathyroid imaging 99mTc – MIBI 9.00 × 10−3
24. Cerebral blood ﬂow 99mTc – exametazine (HMPAO) 9.30 × 10−3
25. Cerebral blood ﬂow 99mTc – ECD (neurolite) 2.20 × 10−3
26. Infection/inﬂammation imaging 67Ga – gallium citrate 1.00 × 10−1
27. Infection/inﬂammation imaging 99mTc – Tc-labelled leucocytes 1.10 × 10−2
28. Infection/inﬂammation imaging 99mTc – monoclonal antibody (LeucoScan) 8.00 × 10−3
six did not reply, giving 25 answers to the survey. This gives a par-
ticipation ratio of answers to the survey of 80% and 81% for 2011
and 2012, respectively. This is an improvement in comparison with
the 73% answer ratio in 2010 (19 NM centres answered the survey,
seven had no statistical data and six did not reply).
The effective dose for each exam and the collective effective dose
were calculated. In order to do that, the average weighted activity






where At is the average activity as reported by NM centre i and
nuclear medicine procedure x. The total number of participant cen-
tres is given by n and freqi(x) represents the frequency of each
examination x in centre i. The dose per caput for each nuclear
medicine procedure is determined as follows:
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ex is the effective dose [] taken from the International Commission
on Radiological Protection (ICRP), the same one applied in the pre-
vious study of DDM2 in Portugal.9 The variable population refers to
the total population of Portugal (10,555,853 inhabitants).13
The total dose per caput due to all NM examination is given
by the sum of each dose determined for each procedure. A lin-
ear correction factor was calculated for 2011 and 2012 in order
to extrapolate the obtained values based on the positive response
ratio. This value is 1.25 (=1/0.80) for 2011 and 1.23 (=1/0.81) for
2012.
A questionnaire was also sent to the 25 nuclear medicine partic-
ipant centres in order to get more information about each centre, to
understand the difﬁculties experienced by healthcare profession-
als in dose assessment and to assess opinions in some important
matters such as the creation of Portuguese guidelines. The ques-
tionnaire sent to the nuclear medicine centres consisted of the
following ﬁve questions:
• Which protocol is used at your centre to determine the activity
administered in a patient?
• If national guidelines were established in order to standardize
the protocols used in medical services, would your centre follow
them?
• Do you usually register the activity values when injecting a
patient, or just the referred protocol value?
• How easily did you separate the activity values and the num-
ber of exams for adult patients from paediatric patients, if this is
possible in your centre?
• In case a separation of the sent data by the patient’s age and sex
would be requested, would it be easy for you to do it?
Results
Population exposure in Portugal for the years 2010, 2011 and 2012
Frequencies
In this work, data for the years 2011 and 2012 were obtained and
compared with the one obtained for 2010. Data showed that 17.97
NM procedures per 1000 population were performed in Portugal in
2010, 13.34 in 2011 and 11.60 in 2012. In Fig. 1 a graph is displayed
showing the trends in the annual frequency of nuclear medicine
exams performed from 2010 to 2012. A reduction on the number
of total nuclear medicine exams and cardiac exams performed in
2011 compared with 2010 is observed. A tiny decrease on the total
and cardiac exams performed is also observed in 2012 in relation
to 2011.
Cardiac exams and their inﬂuence in the results
The cardiac exams considered in this work are: (i) myocardial
perfusion with tetrofosmin (exercise and rest), (ii) myocardial per-
fusion with MIBI (exercise and rest), (iii) myocardial perfusion with
thallium, (iv) MUGA – cardiac blood pool, cardiac blood ﬂow (equi-
librium), and (v) positron emission tomography (PET) – cardiac
study (metabolism and perfusion). In Fig. 2 the annual frequency
of each cardiac exam presented in this study is shown, except for
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Fig. 1. Total annual frequency of NM exams. Inﬂuence of cardiac and bone exami-
nations on the total annual frequency of NM exams.
PET since there is no relevant statistical data. A sharp decrease in
the annual frequency of myocardial perfusion tetrofosmin and MIBI
examination is observed in the last two years compared with 2010.
The MUGA – cardiac blood pool examination did not inﬂuence the
decrease of annual frequency, as its frequency remains constant
along the three years. Finally, myocardium perfusion imaging with
thallium displays a constant and a low number of exams performed
annually.
Collective dose
Applying the conversion factors, as given in Table 1, the
Portuguese total annual average collective effective dose due
to diagnostic nuclear medicine exams was estimated to be
625.6 ± 110.9 manSv (0.059 ± 0.011 mSv  per caput) in 2011 and
565.1 ± 117.3 manSv (0.054 ± 0.011 mSv) in 2012. The dose values
decreased considerably relative to the value estimated for 2010,
840.3 ± 183.8 manSv (0.080 ± 0.017 mSv  per caput). The uncertain-
ties were calculated using the weighted standards deviation of the
reported activities for each centre. Expanding the uncertainty for
each determined collective dose per exam, the uncertainty in the
total collective dose was estimated. Table 2 shows that the col-
lective dose in 2010 due to cardiac exams is more than twice the
value of collective dose calculated in 2012. The values of total col-
lective dose without cardiac exams are very similar amongst the
three years. Finally, the total collective dose is inferior in 2012 also
due to the reduced value of bone imaging examinations.
Exam types
Each of the six different examination groups’ contribution (bone,
heart, thyroid, lung, kidney and remainder) to the annual fre-
quencies and to the total collective dose from nuclear medicine
procedures is shown in Fig. 3. Cardiac procedures are the most
frequently acquired nuclear medicine exams and the ones that
contribute the most for the total collective dose received by the
Portuguese population, although this contribution is diminishing.
Heart and bone exams together correspond to approximately 70%
of the total amount of nuclear medicine exams performed during
the three years studied. In 2010 both categories contributed to 84%
of the total annual dose due to NM procedures, while in 2011 and
2012 that contribution was 70% and 68%, respectively.
The four exams that contributed the most to the high value of
annual collective dose shown in the remainder exams in 2011 and
2012 are neuroendocrine tumours/somatostatin receptors imag-
ing, infection/inﬂammation imaging with gallium, whole body PET
and whole body PET + CT. In 2010 those were the same exams that
contributed the most for the total value of collective effective dose,
amongst the remainder exams, except the contribution of somato-
statin receptors imaging which was  lower (Fig. 4).
TOP 10 of the nuclear medicine exams
In 2010, the 10 nuclear medicine exams that contributed the
most to the total collective effective dose were identiﬁed in the
DDM2-Portugal study (TOP 10). The contribution of each exam is
shown in Fig. 5 for 2010, 2011 and 2012. In 2011 and 2012 the
10 exams that contributed the most to the total collective effective
dose were different than the ones found in 2010. In Table 3 is shown
the TOP 10 exams with higher contribution to the collective effec-
tive dose for the years 2010, 2011 and 2012. In 2011, myocardium
perfusion with thallium contributed 1.7% to the total collective
effective dose, which is no longer on the top 10 exams. Neu-
roendocrine tumours/somatostatin receptors imaging contributed
more to the total collective effective dose in 2011 (3.2%). In 2012,
the contribution of myocardium perfusion examinations with thal-
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Fig. 2. Annual frequency of six nuclear medicine exams in the years 2010, 2011 and 2012.
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Table  2










dose w/o  cardiac
exams (manSv)
Total collective dose w/o
cardiac and bone exams
(manSv)
2010 840.3 453.7 183.28 372.5 189.2
2011  625.6 248.3 178.99 377.4 198.4
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Fig. 3. Relative contribution (%) of six nuclear medicine groups to the total frequency
and  total population dose of nuclear medicine examinations.
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Fig. 4. Relative contribution (%) of remainder exams to the total collective effective
dose.
Table 3
TOP 10 exams for the year 2010, 2011 and 2012.
TOP 10 exams (2010–2012)
Bone imaging
Myocardial perfusion with tetrofosmin (exercise)
Myocardial perfusion with tetrofosmin (rest)
PET – whole body
Myocardial perfusion with MIBI (rest)
Myocardial perfusion with MIBI (exercise)
MUGA, cbp, cbf (equilibrium)
Thyroid imaging (oral uptake, no blocking)
PET – whole body + CT
Myocardial perfusion with thallium
decreased to 1.7%, being no longer in the top 10 exams. Neu-
roendocrine tumours/somatostatin receptors imaging and thyroid
metastases (after ablation, uptake 0%) contributed more to the pop-
ulation’s exposure with 3.94% and 2.9% respectively, more than the
aforementioned examinations.
Portugal and other European countries
The relative contribution of NM procedures to the collective
effective dose (manSv) was calculated for the 35 countries that par-
ticipated in DDM2.6 The report suggested a group of top 7 exams,
selecting the highest examinations’ contributors to the collective
effective dose in all DDM2 countries. These top 7 exams are in
fact 11 examinations. DDM2 report grouped the myocardial per-
fusion with MIBI examination (rest and stress) with myocardial
perfusion with tetrofosmin (rest and stress) in only one examina-
tion called heart exam with 99mTc, while whole body PET + CT and
PET were also grouped in only one exam. The minimum, maximum
and median values were estimated for the identiﬁed exams. The
same calculations were performed to study the Portuguese reality
based on the collective dose data for the year 2010, 2011 and 2012.
The results obtained for Portugal and DDM2 countries are shown
in Fig. 6. The rest and stress myocardial perfusion exams were
grouped, since no information was  available in separate for DDM2
participant countries.6 The bars represent the minimum and max-
imum values identiﬁed for all countries participating in DDM2 and
the Portuguese results between 2010 and 2012. The results differ
greatly between the Portugal and the remainder DDM2 countries,
particularly regarding bone imaging and myocardium perfusion
with MIBI.
For the same 11 examinations in consideration, now separating
the rest from the stress myocardial perfusions exams, the dose per
procedure in mSv  was calculated based on the Portuguese results
between 2010 and 2012. The values were compared again with
DDM2 countries’ results as shown in Fig. 7, and even more so with
the values obtained for neighbouring Spain.14 In terms of absorbed
dose per procedure, the results are similar between Portugal, Spain
and European countries, except for myocardium perfusion image
with thallium, where the difference is higher than 10 mSv  (higher
value in Portugal and inexistent in Spain). The dose per procedure
of thyroid metastases (after ablation, uptake 0%) and whole body
PET exam also show higher values in Portugal.
6 F. Costa et al. / Rev Esp Med  Nucl Imagen Mol. 2015;34(1):1–8
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Fig. 5. TOP 10 of 2010 NM exams that contribute (%) the most to the total collective effective dose of Portuguese population in the years 2010, 2011 and 2012.
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Fig. 6. The examinations that have a higher contribution to the collective effective dose of the European countries reported in the DDM2  study. Relative collective effective
dose  for DDM2 countries and Portugal.
Questionnaire
From the 25 nuclear medicine participant centres, only 12
replied to the survey, although the results given were assumed to
be representative of Portuguese NM centre reality. Of the respon-
dent centres, more than 80% of the NM centres responded to
question 1 that they follow the European Association of Nuclear
Medicine (EANM) guidelines,15 the Society of Nuclear Medicine and
Molecular Imaging (SNMMI) guidelines16 and the British Nuclear
Medicine Society (BNMS) protocol,17 or some form of adaptation.
When asked if they will follow Portuguese guidelines in the second
question, 80% responded positively, however some referred they
had to compare them with the guidelines they already have and
follow for quality assurance. The third question reveals the concern
to know if the Portuguese NM centres register the activity admin-
istered to each patient or just the protocol values. As a response to
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it, 75% of the surveyed centres register the activity values for each
patient, and the others just save the protocol values. Concerning
question 4, only 25% (three centres) had the data already separated
from paediatric and adult patients and for 33% (four centres) it was
easy to separate the data. In question 5 only three centres of the
12 responded that they can provide the data separated by age and
sex.
Discussion
In 2011 and 2012 it was possible to collect data from more
NM centres in Portugal than in 2010. Nevertheless a decrease in
the number of NM exams was observed. This was  mostly due to a
considerable reduction in the number of performed cardiac exam-
inations but also due to a decrease in the bone imaging exams
performed. Among the reasons why the number of cardiac exams
diminished is due to the implementation of improved techniques
for diagnostics (such as echograms) which do not utilize ionizing
radiation. Another contributor could be the ﬁnancial crisis, which
may  have affected the number of prescribed cardiac exams in the
Health care centres. To reinforce this idea, the total number of
NM examination performed during the three years, not counting
the cardiac and bone examinations, are approximately constant
during the three years. The decrease was particularly evident in
the myocardial perfusion with tetrofosmin (exercise and rest) and
myocardial perfusion with MIBI (exercise and rest) examinations.
This explains the reduction in the total annual average collective
dose for the year 2011 and 2012, as well as a reduction in the dose
per caput for each nuclear medicine, when compared with 2010.
Nonetheless a reduction is observed; cardiac exams contin-
ued to be the examination that contributed the most in terms of
number of exams performed and total annual dose in 2011 and
2012, although, with a lower percentage compared with 2010. The
reduced proportion of cardiac examinations explains the higher
relative contribution of the ﬁve other groups of examinations in
the last two years, compared with the results obtained in 2010,
especially the increase in the percentage of bone imaging and
remainder exams performed (Fig. 3). Whole body PET was the
exam that contributed more for the high percentage of remainder
exams, increasing the percentage in 2011 and 2012. This incre-
ment was due to an increase on the number of whole body PET
exams performed in Portugal, while de average collective dose
was approximately constant. Also, somatostatin receptors imag-
ing examination which had contribution that was  low in 2010, but
in 2011 and 2012 it showed a high contribution (Fig. 4). This could
be explained by a great variability on the average activity admin-
istered to the patients for somatostatin receptors imaging among
the participant NM centres in Portugal.
The examinations that have a higher contribution to the rela-
tive collective effective dose of the European countries reported
in DDM2 differ from the Portuguese results, in particular for bone
imaging and myocardium perfusion with MIBI (Fig. 6). Neverthe-
less, a large range is observed in the data compiled in the DDM2
report, in which minimum and maximum values are very different
depending on the considered European country. In terms of average
effective dose per NM procedure, the results obtained for Portugal
are similar with DDM2 reported values, except for myocardial per-
fusion with thallium. This could be due to less robustness in the
available Portuguese data, since this examination is rare in Portugal
(Fig. 2), being only performed in three nuclear medicine centres.
The questionnaire was important to characterize the NM cen-
tres in Portugal and to identify measures that should be taken in
order to standardize the protocols and the way the information is
collected in each centre. The survey reveals that the creation of
Portuguese guidelines is a possibility and should be developed. The
questionnaire was  also alert for the fact that 25% of the surveyed
did not register the activity value administered to each patient,
which means that some centres sent the protocol activity val-
ues, which although are a good approximation to the reality, they
might be biased. Question 4 was  also essential to understand if
the Portuguese healthcare system is prepared to efﬁciently provide
periodic detailed information if needed. More than 50% could eas-
ily provide the data for adult patients only, one centre referred
difﬁculties to separate the data while four said it was  impossible
to separate. This is a concern because it means that some of the
results sent are being inﬂuenced by low activity values adminis-
tered to paediatric patients, thus decreasing estimated values of
collective effective dose of Portuguese population calculated in
this study. In other European countries, data on the age distribu-
tion of patients undergoing nuclear medicine examinations were
available.4 In order to understand if this study is feasible in Portu-
gal question 5 was  asked, however the majority of the centres is not
prepared to provide this type of information, since it will be time
consuming in some cases and even impossible in others where they
do not keep record of the ages of the patients.
Conclusion
This study is a continuity of DDM2 – Portugal, and provides an
estimation of the dose received by Portuguese population in nuclear
medicine exams, following the RP 154 methodology. It was possi-
ble to compile data from more NM centres in the years 2011 and
2012 compared with the data collected in 2010. The main nuclear
medicine centres in Portugal, which annually perform more exam-
ination, participated in this study, allowing us to state that this
study will be very representative of the Portuguese reality. The
annual average effective dose decreased in 2011 and 2012 due to
the reduction of the number of NM exams performed, particularly
due to cardiac exams but also due to bone imaging. Nevertheless,
these two exams continue to be the most frequent exams and the
ones that contributed the most for total population dose. Contact
with nuclear medicine centres is required to better understand
the decrease of NM exams performed, although ﬁnancial problems
seem to be the reason. The high contribution of neuroendocrine
tumours/somatostatin receptors imaging to the annual collective
dose in the years 2011 and 2012 is also of great concern, and
the reasons will be investigated through direct contact with the
healthcare professionals. The Portuguese results of average dose
per procedure are similar with the results presented on the Dose
Datamed 2 report, with an exception of myocardial perfusion with
thallium. The contribution of whole body PET examinations has
also increased, and it is thus important to keep track of these val-
ues in future evaluations of the annual collective dose. In addition
it is important to note that in hybrid techniques such as PET/CT and
SPECT/CT, the dose received by the patient will be higher due to the
dose received by the CT exams, which is not taken into account in
this study. Improvements are still needed to guarantee that all the
centres send the average activity administered to adult patients and
can eventually separate activity values between adults and chil-
dren. It is also expected to expand the participation of NM centres
in Portugal to 100%, through the creation of an on-line platform
to simplify the data share. Nonetheless, we  recommend that all
nuclear medicine centres start to organize the data in the DDM2
data format, since it is expected to perform this study periodically,
in order to identify trends in the annual effective dose and annual
collective dose of Portuguese Population. This will allow for rais-
ing awareness in medical professionals, staff and members of the
public and for potential dose optimization. In addition, the avail-
ability of such data will facilitate the implementation of radiation
protection requirements in Portugal.
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